Health & Safety Industry Today
Neurological Biomarker for Alzheimer and Parkinson Diseases Market Projected to Register Solid 9.8% CAGR, Likely to Reach USD 8.0 Billion by 2035
WiseGuy Reports, Oct. 2025 (Press Release) – The Neurological Biomarker for Alzheimer and Parkinson Diseases Market Global Outlook:
Global Neurological Biomarker for Alzheimer and Parkinson Diseases Market Growth Analysis and Trends Report Application (Disease Diagnosis, Disease Prognosis, Disease Progress Monitoring), By Test Type (Blood Tests, Cerebrospinal Fluid Tests, Imaging Biomarkers), By Biomarker Type (Protein Biomarkers, Genetic Biomarkers, Metabolic Biomarkers), By End User (Hospitals, Diagnostic Laboratories, Research Organizations) and By Regions - Global Industry Forecast 2025 to 2035
Neurological Biomarker for Alzheimer and Parkinson Diseases Market Overview
The Neurological Biomarker for Alzheimer and Parkinson Diseases Market is experiencing rapid growth driven by increasing awareness, technological innovations, and rising global investments in neurological research. Valued at USD 2.87 billion in 2024, the market is expected to reach USD 8.0 billion by 2035, expanding at a robust CAGR of 9.8% during the forecast period from 2025 to 2035. The rising prevalence of Alzheimer’s and Parkinson’s diseases and the growing demand for early diagnostic tools are reshaping the global diagnostics and pharmaceutical landscape.
Market Overview
Neurological biomarkers play a pivotal role in the detection, monitoring, and management of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. These biomarkers help in identifying disease progression at an early stage and assessing therapeutic efficacy. The Neurological Biomarker for Alzheimer and Parkinson Diseases Market is being propelled by continuous innovations in diagnostic platforms and biomarker discovery, alongside a rising geriatric population and regulatory incentives promoting early diagnosis and precision medicine.
The market is projected to grow steadily from USD 3.15 billion in 2025 to USD 8.0 billion by 2035, reflecting a significant shift toward biomarker-based diagnostics and therapeutics.
Request To Free Sample of This Strategic Report: https://www.wiseguyreports.com/sample-request?id=735525
Key Market Dynamics
The growth of the Neurological Biomarker for Alzheimer and Parkinson Diseases Market is influenced by multiple interlinked factors driving both demand and technological adoption.
- Increasing prevalence of neurological disorders globally is fueling the need for reliable biomarkers to improve disease management.
- Advanced diagnostic technologies, such as liquid biopsy and molecular imaging, are enhancing accuracy in early detection.
- Rising investment in biomarker research by pharmaceutical and biotech companies is accelerating biomarker validation and commercialization.
- The aging population worldwide is contributing to a higher incidence of neurodegenerative diseases, thus expanding diagnostic demand.
- Regulatory support for biomarker discovery from agencies like the FDA and EMA is encouraging innovation and faster approval processes.
Regional Insights
The Neurological Biomarker for Alzheimer and Parkinson Diseases Market demonstrates strong geographical segmentation across North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA).
North America dominates the market, primarily led by the U.S., where companies such as Biogen, Pfizer, and Eli Lilly are advancing biomarker-based drug development. The region benefits from robust funding, a mature healthcare system, and strong partnerships between academic institutions and biotechnology firms.
Europe follows closely, with major contributions from the U.K., Germany, and France. The European market is driven by cross-border research collaborations and government-backed programs focused on early diagnosis of dementia and Parkinson’s.
Asia-Pacific is emerging as the fastest-growing region, fueled by expanding healthcare infrastructure, increasing patient awareness, and growing investments in R&D across China, Japan, and India.
South America and MEA are gradually adopting biomarker technologies through public health initiatives and growing collaborations with international research organizations.
Market Segmentation Analysis
The market is segmented by Application, Test Type, Biomarker Type, End User, and Region, offering diversified opportunities across the healthcare ecosystem.
By Application, Alzheimer’s disease dominates due to the high global patient population and ongoing research for disease-modifying therapies. Parkinson’s disease applications are rapidly expanding as researchers focus on early biomarker identification for improved disease management.
By Test Type, imaging biomarkers (PET, MRI) and fluid biomarkers (CSF and blood-based tests) represent the major categories. Fluid-based biomarkers are gaining traction due to their non-invasive nature and cost-effectiveness.
By Biomarker Type, protein-based, genetic, and metabolic biomarkers are the key classifications, with protein biomarkers such as amyloid-beta, tau, and alpha-synuclein gaining widespread clinical attention.
By End User, hospitals and diagnostic centers hold the largest market share, driven by rising adoption of biomarker assays in clinical settings. Research institutions and pharmaceutical companies are also expanding their biomarker discovery programs to support drug development initiatives.
You Can Purchase Complete Report: https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=735525
Competitive Landscape
The Neurological Biomarker for Alzheimer and Parkinson Diseases Market is characterized by the presence of global pharmaceutical giants and specialized biotech firms focusing on biomarker development. Key companies profiled include Quest Diagnostics, Sana Biotechnology, Johnson & Johnson, Amgen, Sanofi, Roche, AbbVie, Pfizer, Biogen, Bristol Myers Squibb, Novartis, Merck, GSK, AstraZeneca, and Eli Lilly.
These companies are investing in clinical trials, precision diagnostics, and multi-omics research to enhance biomarker accuracy and utility. Strategic collaborations and acquisitions are common, enabling firms to expand biomarker portfolios and leverage data-driven insights for drug development. Partnerships between diagnostics and pharmaceutical companies are accelerating the translation of biomarker discoveries into clinical applications.
Key Market Opportunities
The future of the Neurological Biomarker for Alzheimer and Parkinson Diseases Market lies in innovation and data integration. Significant opportunities include:
- Advancements in diagnostic technologies such as AI-based imaging and digital biomarker platforms.
- Rising prevalence of neurodegenerative disorders creating a strong need for early intervention tools.
- Increased funding for neurological research from both public and private sectors, driving faster validation of biomarkers.
- Growing demand for personalized medicine, enhancing patient-specific treatment approaches.
- Expansion of healthcare infrastructure in emerging markets, improving access to advanced diagnostics and neuro care.
Reasons To Buy The Neurological Biomarker for Alzheimer and Parkinson Diseases Market Report:
➼ In-depth analysis of the Neurological Biomarker for Alzheimer and Parkinson Diseases Market on the global and regional levels.
➼ Major changes in market dynamics and competitive landscape.
➼ Segmentation on the basis of type, application, geography, and others.
➼ Historical and future market research in terms of size, share growth, volume, and sales.
➼ Major changes and assessment in market dynamics and developments.
➼ Emerging key segments and regions
➼ Key business strategies by major market players and their key methods
Other Related Reports from Latest WiseGuy Reports:
LFA-Based Cardiac Marker Market
Large Animals for Experiment Market
Medical Brainwave Detector Market
Kallikrein 13 ELISA Kit Market
Iodine-Containing Contrast Medium Market
Lumen Aspiration Needle Market
Low Concentration Atropine Eye Drop Market
About US:
Wise Guy Reports is pleased to introduce itself as a leading provider of insightful market research solutions that adapt to the ever-changing demands of businesses around the globe. We want our clients to have information that can be used to act upon their strategic initiatives. We, therefore, aim to be your trustworthy partner within dynamic business settings through excellence and innovation. By offering comprehensive market intelligence, our company enables corporate organizations to make informed choices, drive growth, and stay ahead in competitive markets
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!
